论文部分内容阅读
目的探讨慢性乙型肝炎患者外周血单个核细胞(PBMC)中部分CXC趋化因子(IP-10、Mig)mRNA表达水平,并比较2种类型干扰素-α(IFN-α)联合利巴韦林治疗后对其表达水平的影响。方法对2004年1月至2005年6月淮南第二矿工医院感染科收治的45例慢性乙型肝炎患者以实时聚合酶链反应(Real-timePCR)法动态检测其经IFN-α联合利巴韦林治疗前、治疗3个月、6个月后PBMC内IP-10、MigmRNA的含量,同时选取同期24例体检正常献血员为对照组,测量其PBMC内IP-10、MigmRNA的含量。2组均以趋化因子与管家基因GAPDH的对数比值为其最终相对表达量。结果慢性乙型肝炎患者治疗前IP-10、MigmRNA表达水平分别为(0.7387±0.0768)、(0.6883±0.0693),显著高于对照组(P<0.001)。IFN-α治疗3个月后IP-10、MigmRNA表达水平分别为(0.5741±0.0912)、(0.5962±0.0987),与治疗前相比,差异有显著性(P<0.05～P<0.001)。IFN-α治疗6个月后IP-10、MigmRNA表达水平分别为(0.4235±0.0924)、(0.4105±0.0898),与治疗前相比,差异有显著性(P<0.001)。普通IFN-α和聚乙二醇化干扰素-α(PEG-IFN-α)治疗后各趋化因子表达水平不同,差异有显著性(P<0.05～P<0.001)。结论慢性乙型肝炎患者PBMC中IP-10、MigmRNA表达升高,普通IFN-α和PEG-IFN-α均能显著下调IP-10、MigmRNA表达水平,PEG-IFN-α治疗组疗效优于普通IFN-α组。IFN这种免疫调节作用,对降低患者体内炎性反应、控制病情发展十分有利。
Objective To investigate the expression of partial CXC chemokines (IP-10, Mig) in peripheral blood mononuclear cells (PBMCs) from patients with chronic hepatitis B and compare the effects of two types of interferon-α (IFN-α) Effect of Lin on its expression after treatment. Methods From January 2004 to June 2005, 45 patients with chronic hepatitis B admitted to the Second Mines Hospital of Huainan Mining Hospital were detected by real-time polymerase chain reaction (Real-time PCR) The levels of IP-10 and MigmRNA in peripheral blood mononuclear cells of PBMCs before treatment, 3 months and 6 months after treatment were measured, and the levels of IP-10 and MigmRNA in PBMC were also measured. In both groups, the logarithmic ratio of chemokine and housekeeping gene GAPDH was the final relative expression. Results The levels of IP-10 and MigmRNA in patients with chronic hepatitis B before treatment were (0.7387 ± 0.0768) and (0.6883 ± 0.0693), respectively, which were significantly higher than those in the control group (P <0.001). The mRNA expressions of IP-10 and MigmRNA in three months after IFN-α treatment were (0.5741 ± 0.0912) and (0.5962 ± 0.0987), respectively, which were significantly different from those before treatment (P <0.05 and P <0.001). The mRNA expressions of IP-10 and MigmRNA in IFN-α group after 6 months treatment were (0.4235 ± 0.0924) and (0.4105 ± 0.0898), respectively, which were significantly different from those before treatment (P <0.001). The expression levels of chemokines were different between normal IFN-α and pegylated interferon-α (P <0.05 ~ P <0.001). Conclusion The expression of IP-10 and MigmRNA in peripheral blood mononuclear cells of patients with chronic hepatitis B were increased. The levels of IP-10 and MigmRNA were significantly decreased by both IFN-α and PEG-IFN-α. The efficacy of PEG-IFN- IFN-α group. The immunomodulatory effects of IFN, in reducing the patient’s inflammatory response, control the development of the disease is very favorable.